tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Hypopigmentation D017496 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Mediastinitis D008480 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mucinoses D017520 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Oliguria D009846 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Labyrinthitis D007762 2 associated lipids
Paraproteinemias D010265 2 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Fungemia D016469 2 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Pharyngitis D010612 2 associated lipids
Histiocytosis D015614 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Leg Injuries D007869 2 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Seminoma D018239 2 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Rupture D012421 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cheilitis D002613 2 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Earache D004433 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Tongue Diseases D014060 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Allen BR et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. 2003 Arch. Dis. Child. pmid:14612358
Lancia P et al. Choosing the right dose of tacrolimus. 2015 Arch. Dis. Child. pmid:25416736
Nishimuta K and Ito Y Effects of metronidazole and tinidazole ointments on models for inflammatory dermatitis in mice. 2003 Arch. Dermatol. Res. pmid:12624780
Ito F et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. 1999 Arch. Dermatol. Res. pmid:10367710
Lubaki LJ et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. 2010 Arch. Dermatol. Res. pmid:19547993
Eberlein-König B et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. 1997 Arch. Dermatol. Res. pmid:9373722
Hultsch T et al. Direct evidence that FK506 inhibition of FcepsilonRI-mediated exocytosis from RBL mast cells involves calcineurin. 1998 Arch. Dermatol. Res. pmid:9681677
García-García B et al. Frosch' surface microscopy score for the assessment of steroid-induced atrophy. 2014 Arch. Dermatol. Res. pmid:24402286
Paus R et al. Hair growth control by immunosuppression. 1996 Arch. Dermatol. Res. pmid:8818191
Furukawa F et al. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. 1995 Arch. Dermatol. Res. pmid:7487142
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Yoon NY et al. Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. 2015 Arch. Dermatol. Res. pmid:25786383
Hofmann M et al. Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy. 2013 Arch. Dermatol. Res. pmid:23242470
Toyota N et al. Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells. 1996 Arch. Dermatol. Res. pmid:8844128
Engelhart K et al. In vitro reproduction of clinical hallmarks of eczematous dermatitis in organotypic skin models. 2005 Arch. Dermatol. Res. pmid:15952007
Hultsch T et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. 1998 Arch. Dermatol. Res. pmid:9808344
Lauerma AI et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. 1994 Arch. Dermatol. Res. pmid:7526805
Borro JM et al. Long-term success of combined kidney-lung transplantation in a patient with cystic fibrosis. 2013 Arch. Bronconeumol. pmid:23427867
Reig Mezquida JP et al. Thrombotic microangiopathy associated with tacrolimus in lung transplantation. 2015 Arch. Bronconeumol. pmid:25138798
Zurbano F et al. Maternity and lung transplantation: cases in Spain. 2012 Arch. Bronconeumol. pmid:22771003
Wen H et al. Characterization of the binding sites for the interactions between FKBP12 and intracellular calcium release channels. 2012 Arch. Biochem. Biophys. pmid:22100703
Vincent SH et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. 1992 Arch. Biochem. Biophys. pmid:1373595
Yin M and Ochs RS Mechanism for the paradoxical inhibition and stimulation of calcineurin by the immunosuppresive drug tacrolimus (FK506). 2003 Arch. Biochem. Biophys. pmid:14592464
Salowe SP and Hermes JD Competitive and slow-binding inhibition of calcineurin by drug x immunophilin complexes. 1998 Arch. Biochem. Biophys. pmid:9675023
Tomono M et al. Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. 1998 Arch. Biochem. Biophys. pmid:9606972
Kakegawa T et al. Rapamycin induces binding activity to the terminal oligopyrimidine tract of ribosomal protein mRNA in rats. 2002 Arch. Biochem. Biophys. pmid:12051685
Mukerjee N et al. Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. 2000 Arch. Biochem. Biophys. pmid:10898953
Fryer JP et al. Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. 1996 Arch Surg pmid:8546583
Harmon JV et al. Experimental short-term immunosuppression after bowel transplantation and donor-specific bone marrow infusion. 2001 Arch Surg pmid:11448397
Echigo Y et al. Effects of cyclosporine and tacrolimus (FK 506) on acute pancreatitis in mice. 1995 Arch Surg pmid:7528496
Freise CE et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. 2003 Arch Surg pmid:14557130
Johnson MW et al. Hepatitis C viral infection in liver transplantation. 1996 Arch Surg pmid:8611094
Stötter H and Lotze MT Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. 1991 Arch Surg pmid:1726819
Sánchez Ferreiro AV and Muñoz Bellido L [Tacrolimus in the treatment of atopic kerato-conjunctivitis]. 2013 Arch Soc Esp Oftalmol pmid:23886369
Rodríguez-Ausín P et al. Topical tacrolimus 0.03% for the treatment of ocular psoriasis. 2016 Arch Soc Esp Oftalmol pmid:27130870
Rybojad M [Atopic dermatitis]. 2012 Arch Pediatr pmid:22796288
Monchaud C et al. [Long lasting side effects of immunosuppressants in children]. 2007 Arch Pediatr pmid:17442546
Geramizadeh B et al. Post-transplantation lymphoproliferative disorder after liver transplantation: report of 5 cases among more than 550 liver transplants in Iran. 2010 Arch Iran Med pmid:20804309
Dehghani SM et al. Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients. 2010 Arch Iran Med pmid:20187665
Yeh C et al. Effect of FK506 on functional recovery after facial nerve injury in the rat. 2007 Sep-Oct Arch Facial Plast Surg pmid:17875826
Travis LB et al. Successful treatment of vitiligo with 0.1% tacrolimus ointment. 2003 Arch Dermatol pmid:12756092
Lepe V et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. 2003 Arch Dermatol pmid:12756094
Plettenberg H et al. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. 2003 Arch Dermatol pmid:12756103
Lübbe J et al. Adults with atopic dermatitis and herpes simplex and topical therapy with tacrolimus: what kind of prevention? 2003 Arch Dermatol pmid:12756112
Ruzicka T et al. Tacrolimus: the drug for the turn of the millennium? 1999 Arch Dermatol pmid:10328199
Laffitte E et al. Erosive pustular dermatosis of the scalp: treatment with topical tacrolimus. 2003 Arch Dermatol pmid:12810500
Chu J et al. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. 2003 Arch Dermatol pmid:12810523
Allen A et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. 2001 Arch Dermatol pmid:11405764
Qureshi AA and Fischer MA Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. 2006 Arch Dermatol pmid:16702502
Eichenfield LF et al. 1% pimecrolimus cream for atopic dermatitis. 2003 Arch Dermatol pmid:14568846
Thiers BH Topical tacrolimus: treatment failure in a patient with alopecia areata. 2000 Arch Dermatol pmid:10632221
Rotunda AM et al. Hyperkeratotic plaques on the palms and soles. Palmoplantar lichen planus, hyperkeratotic variant. 2004 Arch Dermatol pmid:15492196
Laffitte E and Panizzon RG Is topical tacrolimus really an effective therapy for Hailey-Hailey disease? 2004 Arch Dermatol pmid:15492199
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. 1996 Arch Dermatol pmid:8629845
Bernard LA et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. 2003 Arch Dermatol pmid:12588240
Zonneveld IM et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. 1998 Arch Dermatol pmid:9762021
Jegasothy BV et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. 1992 Arch Dermatol pmid:1376102
Choi CJ and Nghiem P Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. 2001 Arch Dermatol pmid:11559218
Mandelin J et al. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. 2010 Arch Dermatol pmid:20956662
Lebwohl M et al. Proven efficacy of tacrolimus for facial and intertriginous psoriasis. 2005 Arch Dermatol pmid:16172314
Neill SM and Lewis FM Vulvovaginal lichen planus: a disease in need of a unified approach. 2008 Arch Dermatol pmid:19015426
Gorman CR and White SW Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. 2005 Arch Dermatol pmid:16172323
Heffernan MP et al. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. 2005 Arch Dermatol pmid:16172325
Lally A et al. Penile pyoderma gangrenosum treated with topical tacrolimus. 2005 Arch Dermatol pmid:16172330
Le Cleach L et al. Is topical monotherapy effective for localized pyoderma gangrenosum? 2011 Arch Dermatol pmid:21242400
Pomerantz RG et al. Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. 2010 Arch Dermatol pmid:20479299
Ehst BD and Warshaw EM Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. 2004 Arch Dermatol pmid:15313828
Sand C and Thomsen HK Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease. 2003 Arch Dermatol pmid:14623698
Sagransky MJ et al. A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. 2010 Arch Dermatol pmid:21173330
Laino L and DiCarlo A Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. 2011 Arch Dermatol pmid:21690553
Eiling E et al. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. 2008 Arch Dermatol pmid:18794482
Byrd JA et al. Response of oral lichen planus to topical tacrolimus in 37 patients. 2004 Arch Dermatol pmid:15611431
Santos-Juanes J et al. Topical tacrolimus: an effective therapy for Zoon balanitis. 2004 Arch Dermatol pmid:15611442
Milingou M et al. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. 2004 Arch Dermatol pmid:15611445
Guenova E et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. 2011 Arch Dermatol pmid:21680759
Singh MN et al. Solitary cutaneous nodule in an immunocompromised patient. 2007 Arch Dermatol pmid:18087016
Ng W and Ikeda S Mount Tsukuba and the origin of tacrolimus. 2009 Arch Dermatol pmid:19289758
Sardana K et al. Effect of tacrolimus on vitiligo in absence of UV radiation exposure. 2007 Arch Dermatol pmid:17224558
Patel RR et al. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. 2003 Arch Dermatol pmid:12975161
Nagao K et al. A case of generalized pustular psoriasis treated with topical tacrolimus. 2003 Arch Dermatol pmid:12975175
Yan AC et al. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. 2010 Arch Dermatol pmid:20083693
Ciurea AM et al. Complete and durable clinical response of malignant pyoderma to tacrolimus in combination with dapsone and prednisone. 2010 Arch Dermatol pmid:20083712
Castelo-Soccio L et al. Induced lentiginosis with use of topical calcineurin inhibitors. 2012 Arch Dermatol pmid:22710469
Ward KM et al. Eyelash trichomegaly associated with systemic tacrolimus. 2006 Arch Dermatol pmid:16490862
Ostovari N et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. 2006 Arch Dermatol pmid:16490866
Mikhail M et al. Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. 2008 Arch Dermatol pmid:18427063
Chapman MS et al. 0.1% tacrolimus ointment for the treatment of intertrigo. 2005 Arch Dermatol pmid:15967933
Olivier V et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. 2002 Arch Dermatol pmid:12374539
Kunstfeld R et al. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. 2003 Arch Dermatol pmid:12873877
Böhm M et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. 2003 Arch Dermatol pmid:12873890
Shah KN and Yan AC Low but detectable serum levels of tacrolimus seen with the use of very dilute, extemporaneously compounded formulations of tacrolimus ointment in the treatment of patients with netherton syndrome. 2006 Arch Dermatol pmid:17043199
Banky JP et al. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. 2004 Arch Dermatol pmid:15262686
Passeron T et al. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. 2007 Arch Dermatol pmid:17438179
Bruce A and Rogers RS New and old therapeutics for oral ulcerations. 2007 Arch Dermatol pmid:17438186
Qureshi A and Fischer MA Topical calcineurin inhibitors revisited. 2007 Arch Dermatol pmid:17438195
Carroll PB et al. Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results. 1994 Arch Dermatol pmid:7526802
Rapaport MJ Topical tacrolimus. 2005 Arch Dermatol pmid:16301404
Cheng A and Mann C Oral erosive lichen planus treated with efalizumab. 2006 Arch Dermatol pmid:16785369
Mackelfresh J et al. Combination therapy of doxycycline and topical tacrolimus for venous ulcers. 2005 Arch Dermatol pmid:16301410
Hall VC et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. 2003 Arch Dermatol pmid:12925404